Mon panier

IGFBP-3

IGFBP-3 Informations sur la molécule

Nom anglaisInsulin-like growth factor binding protein IIINombre de médicaments commercialisés0
Nombre de médicaments cliniques2Alias de la cible
Phase de R&D la plus avancéePhase 2 Clinical
Nom anglaisInsulin-like growth factor binding protein III
Alias de la cible
Nombre de médicaments commercialisés0
Nombre de médicaments cliniques2
Phase de R&D la plus avancéePhase 2 Clinical

IGFBP-3 Liste de produits

  • Attribut

    Protein (2)

  • Bibliothèque de produits

    En ligne (2)

  • Espèces

    Human (2)

  • Étiquette

    His Tag (1)Fc Tag (1)

  • Marqueur

    Unconjugated (2)

Numéro de produitEspècesSystème d'expressionDescription du produitStructure protéiquePuretéCaractéristiquesPré-commande/Commande
IG3-H5253
Human
HEK293
Human IGFBP-3 (28-291) Protein, Fc Tag
Ajouter au panier
IG3-H52H9
Human
HEK293
Human IGFBP-3 Protein, His Tag
Ajouter au panier
Quantité totale2
  • 1

IGFBP-3Contexte de la molécule

Insulin-like growth factor-binding protein 3 is also known as IGFBP3, is a protein that, in humans, is encoded by the IGFBP3 gene. IGFBP3 forms a ternary complex of about 140 ~150 kDa with IGF1 or IGF2 and a glycoprotein insulin-like growth factor acid-labile subunit (ALS), thus alter the interaction of IGFs with their cell surface receptors. IGFBP3 exerts either proapoptotic or growth stimulatory effects depending upon the cellular context. Studies have shown that IGFBP3 can leads to the induction of apoptosis dependent or independent of the IGF-IGF receptor axis, accordingly acts as a negative regulator of tumorigenesis and progressing in certain carcinomas. The highest expression level is found in the nonparanchymal cells of the liver. Expression levels are also higher during extrauterine life and peak during puberty.

Informations sur les médicaments cliniques

Nom anglaisCode de recherchePhase de R&DEntrepriseIndicationEssai clinique
Mecasermin RinfabaterhIGF-I/rhIGFBP-3; TAK-607; OHB-607; IGF-I/IGFBP-3; SHP-607; HGT-ROP-001Phase 2 ClinicalInsmedBronchopulmonary Dysplasia; Cerebral Intraventricular Hemorrhage; Failure to Thrive; Laron Syndrome; Lung Diseases; Myotonic Dystrophy; Noonan Syndrome; Retinopathy of Prematurity
Details
ENT-001Ent-001; ENT-001; Ent001Phase 1 ClinicalOspedale San RaffaeleDiabetes Mellitus, Type 1; Inflammatory Bowel Diseases
Details
  • Informations sur la molécule
  • Liste de produits
  • Informations sur les médicaments cliniques